Abstract

Inhibition of leukotriene biosynthesis has been extensively studied as a potential for the development of novel therapies for inflammation, respiratory diseases and, in particular, for asthma. We have designed specific functional inhibitors against 5-Lipoxygenase (5-LOX) using several virtual screening techniques like Homology modeling, MD simulations, Docking and Pharmacophore studies. We have identified 6 analogues of novel 5-LOX inhibitors (IC50 < 19 nM) using pharmacophore models and docking studies and their drug like properties were evaluated. These 6 compounds can be taken for further study including synthesis. 5-LOX (5- Lipoxygenase) was found to be a cytosolic enzyme and contained a non-heme iron atom and calcium. This iron atom is critical to determine the catalytic potential of the enzyme, with oxidation to the ferric (Fe3+) form conferring activity (1). 5-LOX can be activated by an increase in intracellular Ca2+ concentration, diacylglycerols, phosphorylation by MAPKAP (mitogen-activated protein kinase-activated protein kinase) kinase-2 and ERK (Extracellular Receptor Kinase) (2). In the absence of calcium, 5-LOX has minimal catalytic activity. The addition of calcium stimulates both the oxygenation and dehydration reactions of 5-LOX. This enzyme is expressed mainly in leukocytes, in line with the function of leukotrienes as mediators of immune reactions (3). Granulocytes, monocytes/macrophages, mast cells, dendritic cells and B lymphocytes express 5-LOX, whereas platelets, endothelial cells, T cells and erythrocytes do not. 5-lipoxygenase (5- LOX) catalyzes the first two steps in the synthesis of all LTs (Leukotriene's), namely the oxidation of AA to 5- hydroperoxyeicosatetraenoic acid (5HPETE) followed by the dehydration of 5-HPETE to LTA (4). 5-Lipoxygenase has a central role in the biosynthesis of leukotrienes. This enzyme initializes the formation of proinflammatory leukotrienes from arachidonic acid (AA). The potent biological effects of Leukotriene's (LTs) includes leukocyte

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call